In 2018, lenvatinib (Lenvima), a multikinase inhibitor targeting VEGFR1-3, FGFR1-4, PDGF alpha (PDGFRα), rearranged during transfection receptor (RET) proto-oncogene receptor tyrosine kinase, and KIT proto-oncogene receptor tyrosine kinase (KIT), was approved by European and Asian food and drug administration (FDA) authorities as an alternative first-line agent for the treatment of patients with unresectable HCC. The gene discussed is FLT1; the disease is hepatocellular carcinoma.